Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013)

The Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients

研究成果: Comment/debate

摘要

In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused.

原文English
頁(從 - 到)749-750
頁數2
期刊Journal of the Formosan Medical Association
117
發行號8
DOIs
出版狀態Published - 2018 八月 1

指紋

Taiwan
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Guidelines
Lipids
corrigendum
Therapeutics
AMG 145

All Science Journal Classification (ASJC) codes

  • Medicine(all)

引用此文

@article{e07705c0b738495083a8e3068e123273,
title = "Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013)",
abstract = "In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused.",
author = "{The Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients} and Yi-Heng Li and Ueng, {Kwo Chang} and Jeng, {Jiann Shing} and Charng, {Min Ji} and Lin, {Tsung Hsien} and Chien, {Kuo Liong} and Wang, {Chih Yuan} and Ting-Hsing Chao and Ping-Yen Liu and Su, {Cheng Huang} and Chien, {Shih Chieh} and Liou, {Chia Wei} and Tang, {Sung Chun} and Lee, {Chun Chuan} and Yu, {Tse Ya} and Chen, {Jaw Wen} and Wu, {Chau Chung} and Yeh, {Hung I.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.jfma.2018.07.007",
language = "English",
volume = "117",
pages = "749--750",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",
number = "8",

}

TY - JOUR

T1 - Erratum

T2 - ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013)

AU - The Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients

AU - Li, Yi-Heng

AU - Ueng, Kwo Chang

AU - Jeng, Jiann Shing

AU - Charng, Min Ji

AU - Lin, Tsung Hsien

AU - Chien, Kuo Liong

AU - Wang, Chih Yuan

AU - Chao, Ting-Hsing

AU - Liu, Ping-Yen

AU - Su, Cheng Huang

AU - Chien, Shih Chieh

AU - Liou, Chia Wei

AU - Tang, Sung Chun

AU - Lee, Chun Chuan

AU - Yu, Tse Ya

AU - Chen, Jaw Wen

AU - Wu, Chau Chung

AU - Yeh, Hung I.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused.

AB - In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85050115418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050115418&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2018.07.007

DO - 10.1016/j.jfma.2018.07.007

M3 - Comment/debate

C2 - 30037521

AN - SCOPUS:85050115418

VL - 117

SP - 749

EP - 750

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 8

ER -